Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.
Phase of Trial: Phase II
Latest Information Update: 02 Sep 2014
At a glance
- Drugs SAR 407899 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Sanofi
- 21 Jul 2012 Planned end date changed from 26 Aug 2010 to 11 Sep 2010 as reported by European Clinical Trials Database.
- 14 Jul 2012 Actual initiation date changed from 26 Nov 2009 to 11 Dec 2009, as reported by European Clinical Trials Database.
- 21 Apr 2012 Additional location (Germany) added as reported by European Clinical Trials Database record.